The Reagan-Udall Foundation, a collaborative partner with the FDA in investigating CTP, has chosen the United States of the Clinton era.
According to Politico, Jane Henney, the commissioner of the Food and Drug Administration (FDA), will lead a 60-day review of the agency's food safety and tobacco division (CTP) operations. Henney is the first female leader of the Reagan-Udall Foundation and has previously worked at the FDA. This news has not been officially announced yet.
US Food and Drug Administration Commissioner, Robert Califf, has taken this action in order to overcome several controversies during his second term. These controversies include his issuance of a marketing denial order (MDO) to e-cigarette manufacturer Juul Labs, which he later had to rescind.
To learn more about legal disputes between the FDA and electronic cigarette companies, click on the "FDA and Electronic Cigarette Company Legal Dispute Summary" special feature, continuously updated by 2FIRSTS.
Statement:
This article is compiled based on third-party information and is intended for industry exchange and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot verify the authenticity or accuracy of its content. Its translation is intended for industry exchange and research purposes only.
Due to limitations in translation ability, the compiled article may not perfectly reflect the original text. Therefore, it is recommended to refer to the original text for accuracy.
2FIRSTS maintains complete consistency with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and positions.
Copyrights for compiled information belong to the original media and authors. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
